Gastrointestinal and Hepatobiliary Symptoms and Disorders with Long (Chronic) COVID Infection

Rizvi, Anam; Ziv, Yonatan; Crawford, James M.; Trindade, Arvind J.

doi:10.1016/j.gtc.2022.09.002

Cited by 8 publications

(4 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have also examined the relationship between gastrointestinal diseases and LC-19. These studies have found that stomach pain is also a risk factor for suffering from several infections associated with COVID-19 [50,51].…”

Section: Discussionmentioning

confidence: 99%

Identifying Risk Factors and Predicting Long COVID in a Spanish Cohort

Teruel,

Andreu,

Reina

et al. 2024

Preprint

View full text Add to dashboard Cite

Many studies have investigated symptoms, comorbidities, demographic factors, and vaccine effectiveness in relation to long COVID (LC-19) across global populations. However, a number of these studies have shortcomings, such as inadequate LC-19 categorisation, lack of sex disaggregation, or a narrow focus on certain risk factors like symptoms or comorbidities alone. We address these gaps by investigating the demographic factors, comorbidities, and symptoms present during the acute phase of primary COVID-19 infection among patients with LC-19 and those who experienced reinfection, comparing them to typical COVID-19 patients. Additionally, we assess the impact of COVID-19 vaccination on these patients. Drawing on data from the Regional Health System of the Region of Murcia in southeastern Spain, our analysis includes comprehensive information from clinical and hospitalisation records, symptoms, and vaccination details of over 675126 patients across 10 hospitals.We calculated age and sex-adjusted odds ratios (AOR) to identify protective and risk factors for LC-19. Our findings reveal distinct symptomatology, comorbidity patterns, and demographic characteristics among patients with LC-19 versus those with typical COVID-19. Notably, factors such as age, female sex (AOR = 1.39, adjusted p <0.001), symptoms such as chest pain (AOR >1.55, adjusted p <0.001) or hyposmia (AOR >1.5, adjusted p <0.001) and being vaccinated (AOR = 0.10, adjusted p <0.001) significantly influence the risk of LC-19. Interestingly, symptoms and comorbidities show no significant differences when disaggregated by type of LC-19 patient. Vaccination before infection is the most important factor and notably decreases the likelihood of long COVID. Particularly, mRNA vaccines offer more protection against developing LC-19 than viral vector-based vaccines (AOR = 0.48). Additionally, we have developed a model to predict LC-19 that incorporates all studied risk factors, achieving a balanced accuracy of 73% and ROC-AUC of 0.80. This model is available as a free online LC-19 calculator, accessible at (LC-19 Calculator).

show abstract

Section: Discussionmentioning

confidence: 99%

Identifying Risk Factors and Predicting Long COVID in a Spanish Cohort

Teruel,

Andreu,

Reina

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…These manifestations could also occur in adults who experience mild COVID-19; therefore, they are not related to the severity of acute infection. There is no association between gastrointestinal manifestations in long COVID and ethnicity or sex [179].…”

Section: Gastrointestinal Manifestationsmentioning

confidence: 92%

“…Researchers found that gut dysbiosis persists for months, also after SARS-CoV-2 clearance, and contributes to long-term symptoms [182]. In particular, the depletion of commensal anti-inflammatory gut bacteria was observed, which correlated with an increase in the C-reactive protein and, consequently, a pro-inflammatory state [179].…”

Section: Gastrointestinal Manifestationsmentioning

confidence: 99%

Long COVID in Children, Adults, and Vulnerable Populations: A Comprehensive Overview for an Integrated Approach

Calcaterra,

Zanelli,

Foppiani

et al. 2024

Diseases

View full text Add to dashboard Cite

Long COVID affects both children and adults, including subjects who experienced severe, mild, or even asymptomatic SARS-CoV-2 infection. We have provided a comprehensive overview of the incidence, clinical characteristics, risk factors, and outcomes of persistent COVID-19 symptoms in both children and adults, encompassing vulnerable populations, such as pregnant women and oncological patients. Our objective is to emphasize the critical significance of adopting an integrated approach for the early detection and appropriate management of long COVID. The incidence and severity of long COVID symptoms can have a significant impact on the quality of life of patients and the course of disease in the case of pre-existing pathologies. Particularly, in fragile and vulnerable patients, the presence of PASC is related to significantly worse survival, independent from pre-existing vulnerabilities and treatment. It is important try to achieve an early recognition and management. Various mechanisms are implicated, resulting in a wide range of clinical presentations. Understanding the specific mechanisms and risk factors involved in long COVID is crucial for tailoring effective interventions and support strategies. Management approaches involve comprehensive biopsychosocial assessments and treatment of symptoms and comorbidities, such as autonomic dysfunction, as well as multidisciplinary rehabilitation. The overall course of long COVID is one of gradual improvement, with recovery observed in the majority, though not all, of patients. As the research on long-COVID continues to evolve, ongoing studies are likely to shed more light on the intricate relationship between chronic diseases, such as oncological status, cardiovascular diseases, psychiatric disorders, and the persistent effects of SARS-CoV-2 infection. This information could guide healthcare providers, researchers, and policymakers in developing targeted interventions.

show abstract

“… 9 Patients with NAFLD and COVID-19 also exhibit an increased prevalence of liver function abnormalities (50%–59% vs. 14%–53% in the general population). 5 , 10 These hepatic abnormalities and dysfunction may persist up to 2 months after a negative SARS-CoV-2 test result 11 and more importantly, can potentially exacerbate NAFLD progression, thereby increasing the risk of developing nonalcoholic steatohepatitis (NASH) and hepatic fibrosis. 6 , 12 , 13 Therefore, implementing appropriate hepatoprotective measures for individuals with NAFLD in the face of SARS-CoV-2 infection is critical.…”

Section: Introductionmentioning

confidence: 99%

Inactivated vaccines reduce the risk of liver function abnormality in NAFLD patients with COVID-19: a multi-center retrospective study

Chen,

Tang,

Feng

et al. 2024

eBioMedicine

View full text Add to dashboard Cite

Gastrointestinal and Hepatobiliary Symptoms and Disorders with Long (Chronic) COVID Infection

Cited by 8 publications

References 100 publications

Identifying Risk Factors and Predicting Long COVID in a Spanish Cohort

Identifying Risk Factors and Predicting Long COVID in a Spanish Cohort

Long COVID in Children, Adults, and Vulnerable Populations: A Comprehensive Overview for an Integrated Approach

Inactivated vaccines reduce the risk of liver function abnormality in NAFLD patients with COVID-19: a multi-center retrospective study

Contact Info

Product

Resources

About